Interferon-α combined with cytarabine in chronic myelogenous leukemia - Clinical benefits

Leukemia and Lymphoma

Volumn 41, Issue 5-6, 2001, Pages 523-533

  Lindauer, M ^a   Fischer, Th ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Chronic myeloid leukemia; CML; Interferon and cytarabine

Indexed keywords

ALPHA INTERFERON; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYTARABINE; DEOXYCYTIDINE; DNA; DNA POLYMERASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE; HYBRID PROTEIN; HYDROXYUREA; IMATINIB; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; NUCLEOSIDE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; RETINOID DERIVATIVE; RIBONUCLEASE; STAT PROTEIN; TYROSINE KINASE RECEPTOR;

ADULT; AGRANULOCYTOSIS; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL STUDY; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FEVER; GASTROINTESTINAL SYMPTOM; HEMATOLOGY; HEPATITIS; HUMAN; LEUKEMIA REMISSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MENTAL DISEASE; MONOTHERAPY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PUBLICATION; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0034895104     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109060343     Document Type: Article

References (64)

1. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: Effects of mismatching for one HLA-locus
2. Treatment of chronic myeloid leukemia by marrow transplantation
3. Bone marrow transplantation for chronic myeloid leukemia: Long-term results
4. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia
5. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
6. Chronic myeloid leukemia trialists collaborative group Interferon a versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials
7. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy
8. Monitoring treatment and survival in chronic myeloid leukemia
9. Low-dose cytosine arabinoside in early and advanced chronic granulocytic leukemia
10. Evidence for a selective antileukemic effect of cytosine arabinoside in patients with chronic granulocytic leukemia
11. Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine
12. Complete cytogenetic response in chronic myelocytic leukemia using α IFN plus hydroxyurea with or without low dose cytosine arabinoside
13. Cytogenetic remissions in chronic myelogenous leukemia using interferon α-2a and hydroxyurea with or without low dose cytosine-arabinoside
14. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine
15. Combined interferon α 2a and cytosine arabinoside as first line treatment for chronic myeloid leukemia
16. Combined α-interferon and low dose cytosine arabinoside for Ph+ chronic phase myeloid leukemia
17. Interferon α-2C and LD ara-C for the treatment of patients with CML: Results of the Austrian multicenter phase II study
18. Efficacy and toxicity of IFN-α2b combined with cytarabine in chronic myelogenous leukemia
19. Interferon α-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
20. Long-term follow-up results of α-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia
21. Cytarabine increases karyotypic response in α-IFN treated chronic myeloid leukemia patients: Results of a national prospective randomized trial
22. Treatment of philadelphia chromosome-positive early chronic phase chronic myeloid leukemia with daily doses of interferon-α and low-dose cytarabine
23. Chronic myeloid leukemia from basics to bedside
24. Biological consequences of the BCR/ABL fusion gene in humans and mice
25. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
26. Blockade of the Bcr-Ab1 Kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-x1
27. Cell biology of CML cells
28. Chronic myelogenous leukemia: A concise update
29. Prognostic discrimination in "good-risk" chronic granulocytic leukemia
30. Collection of normal blood repopulating cells during early haematopoietic recovery after intense conventional chemotherapy in chronic myelogenous leukemia
31. Mobilization/Transplantation of Ph1-negative blood progenitor cells in chronic myelogenous leukemia
32. Treatment of marrow stoma with interferon-α restores normal β1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. Role of MIP-1 α
33. Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML
34. Autologous transplantation of in vivo purged PBSC in CML: Comparison of FISH, cytogenetics, and PCR detection of Philadelphia chromosome in leukapheresis
35. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia
36. Hematologic remission and cytogenetic improvement induced by recombinant human interferon α-2a in chronic myelogenous leukemia
37. Clinical investigation of human α interferon in chronic myelogenous leukemia
38. Interferon α-2b as therapy for Ph-positive chronic myelogenous leukemia: A study of 82 patients treated with intermittent or daily administration
39. Prolonged subcutaneous administration of recombinant α-2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration Cancer and leukemia group B study 8583
40. Interferon α-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
41. Kouseishou leukemia study group A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase
42. Progress with interferon in CML - Results of the MRC UK CML III study
43. Interferon α2c therapy of patients with chronic myelogenous leukemia: Long term results of a multicenter phase-II study
44. Randomized study on hydroxyurea alone versus hydroxyurea combined with low dose interferon-α 2b for chronic myeloid leukemia
45. Treatment of chronic myelogenous leukemia: Current status and investigational options
46. Interferon-α overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stroma cells
47. Apoptosis and proliferation (PCNA labelling) in CML: A comparative immunohistological study of the bone marrow biopsies following interferon and busulphan therapy
48. Regulation of cytokine expression by interferon-α in human bone marrow stromal cells: Inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist
49. Induction of interferon regulatory factors, 2′-5′ oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukemia cells and its relationship to clinical responsiveness
50. IFN-α regulates IL 10 production by CML cells in vitro
51. Antimetabolites
52. Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia
53. Combined cytosine arabinoside plus interferon alpha interferon α potentiates the effect of cytosine arabinoside in HL60 cells and is synergistic in in vivo treatment regimen
54. Autologous transplantation therapy for chronic myelogenous leukemia
55. Characterization of the differential response of normal and CML hematopoietic progenitor cells to macrophage inflammatory protein 1-α
56. Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients
57. Interferon-α for the treatment of elderly patients with chronic myeloid leukemia
58. An evidence based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the american society of hematology
59. Response to recombinant interferon a in patients with chronic myelogenous leukemia in a single center: Results and analysis of predictive fators
60. A pilot study of all-trans retinoic acid in patients with philadelphia chromosome-positive chronic myelogenous leukemia
61. Sequential homoharringtonine and interferon produce high hematologic and cytogenetic response rates in philadelphia chromosome positive chronic myelogenous leukemia
62. GM-CSF can improve the cytogenetic response obtained with interferon-α therapy in patients with chronic myelogenous leukemia
63. Efficiacy of an ABL tyrosine kinase inhibitor in conjunction with other anti-neoplastic agents against BCR-ABL positive cells
64. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy of CML